Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
La radiologia medica
Erschienen in: La radiologia medica 2/2014

01.02.2014 | Head and Neck Radiology

Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma

verfasst von: Fabio Pomerri, Anna Rita Cervino, Faise Al Bunni, Laura Evangelista, Pier Carlo Muzzio

Erschienen in: La radiologia medica | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) has proved effective in detecting recurrent or metastatic differentiated thyroid carcinoma (DTC) in the follow-up of operated DTC patients with high thyroglobulin (Tg) levels and negative findings on radioiodine whole-body scan. The aim of this retrospective study was to assess the impact of PET/CT on the planning of appropriate treatment for known recurrent disease in operated DTC patients.

Materials and methods

The study concerned 44 consecutive DTC patients (36 papillary, 8 follicular), who underwent total thyroidectomy and thyroid remnant ablation with 131I and PET/CT. All patients had proven or strongly suspected recurrent disease judging from neck ultrasound (US) and fine-needle aspiration cytology, and detectable basal Tg levels.

Results

PET/CT findings were positive in 25/44 patients (56.81 %) and negative in 19. A positive PET/CT result predicted resectable tumour recurrences in 19/25 patients, but also detected additional tumour sites that prompted changes to the treatment plan in 6/25 patients (24 %). A negative PET/CT result led to clinical monitoring for 11/19 patients (57.89 %).

Conclusions

PET/CT can help select patients, who might benefit from a tailored therapy by improving the detection of local recurrences not apparent on neck US or metastases.
Literatur
1.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
2.
Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306PubMedCrossRef
3.
Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463PubMedCrossRef
4.
Hay ID, McConahey WM, Goellner JR (2002) Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241–260PubMedCentralPubMed
5.
Pace L, Klain M, Albanese C et al (2006) Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging 33:179–183PubMedCrossRef
6.
Watkinson JC, Franklyn JA, Olliff JF (2006) Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid 16:187–194PubMedCrossRef
7.
Mazzaferri EL, Robbins RJ, Spencer CA et al (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441PubMedCrossRef
8.
Schlumberger M, Berg G, Cohen O et al (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105–112PubMedCrossRef
9.
Bachelot A, Leboulleux S, Baudin E et al (2005) Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 62:376–379CrossRef
10.
Torlontano M, Crocetti U, Augello G et al (2006) Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 91:60–63PubMedCrossRef
11.
Caleo O, Maurea S, Klain M et al (2008) Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose. Radiol Med 113:278–288PubMedCrossRef
12.
Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673PubMedCrossRef
13.
Krishnamurthy S, Bedi DG, Caraway NP (2001) Ultrasound-guided fine-needle aspiration biopsy of the thyroid bed. Cancer 93:199–205PubMedCrossRef
14.
Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G (1998) Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 39:1542–1546PubMed
15.
Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC (2001) Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804–811PubMedCrossRef
16.
Helal BO, Merlet P, Toubert ME et al (2001) Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464–1469PubMed
17.
Pacini F, Agate L, Elisei R et al (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092–4097PubMedCrossRef
18.
Palmedo H, Bucerius J, Joe A et al (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616–624PubMed
19.
Freudenberg LS, Frilling A, Kühl H et al (2007) Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 17:3139–3147PubMedCrossRef
20.
Iagaru A, Kalinyak JE, McDougall IR (2007) F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32:690–695PubMedCrossRef
21.
Mirallié E, Guillan T, Bridji B et al (2007) Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 142:952–958PubMedCrossRef
22.
Shammas A, Degirmenci B, Mountz JM et al (2007) 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221–226PubMed
23.
Salvatore B, Paone G, Klain M et al (2008) Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Q J Nucl Med Mol Imaging 52:2–8PubMed
24.
Bertagna F, Bosio G, Biasiotto G et al (2009) F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 34:756–761PubMedCrossRef
25.
Leboulleux S, Schroeder PR, Busaidy NL et al (2009) Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94:1310–1316PubMedCrossRef
26.
Kaneko K, Abe K, Baba S et al (2010) Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med 35:6–11PubMedCrossRef
27.
Seo JH, Lee SW, Ahn BC, Lee J (2010) Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 72:558–563CrossRef
28.
Vera P, Kuhn-Lansoy C, Edet-Sanson A et al (2010) Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-d-glucose improve detection of recurrence of well differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid 20:15–23PubMedCrossRef
29.
Abraham T, Schöder H (2011) Thyroid cancer—indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 41:121–138PubMedCrossRef
30.
American Joint Committee on Cancer (2002) In: Greene FL, Page DL, Fleming ID et al (eds) Thyroid Cancer, 6th edn. Springer, New York, pp 89–98
31.
Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200PubMedCentralPubMedCrossRef
32.
Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R (2003) Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90–96PubMedCrossRef
33.
Piccardo A, Foppiani L, Morbelli S et al (2011) Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan? Q J Nucl Med Mol Imaging 55:57–65PubMed
34.
Bannas P, Derlin T, Groth M et al (2012) Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Ann Nucl Med 26:77–85PubMedCrossRef
35.
Na SJ, Yoo IeR, O JH et al (2012) Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med 26:26–34PubMedCrossRef
36.
Feine U, Lietzenmayer R, Hanke JP et al (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468–1472PubMed
Metadaten
Titel
Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma
verfasst von
Fabio Pomerri
Anna Rita Cervino
Faise Al Bunni
Laura Evangelista
Pier Carlo Muzzio
Publikationsdatum
01.02.2014
Verlag
Springer Milan
Erschienen in
La radiologia medica / Ausgabe 2/2014
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-013-0323-6

Weitere Artikel der Ausgabe 2/2014

La radiologia medica 2/2014 Zur Ausgabe

Vascular and Interventional Radiology

Endovascular treatment of spontaneous extraperitoneal haemorrhage: immediate and long-term clinical efficiency

Chest Radiology

Saber-sheath trachea as a marker of severe airflow obstruction in chronic obstructive pulmonary disease

Ultrasonography

Ultrasound-guided anterior axilla musculocutaneous nerve block

Abdominal Radiology

Solid pseudopapillary tumour of the pancreas: distinct patterns of computed tomography manifestation for male versus female patients

Resources Management and Health Economy

Work stress and metabolic syndrome in radiologists: first evidence

Musculoskeletal Radiology

Magnetic resonance imaging (MRI) artefacts in hip prostheses: a comparison of different prosthetic compositions

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise